# Cellectar Biosciences Inc. (CLRB)

Source: https://www.quantisnow.com/company/CLRB
Generated: 2026-11-08T23:15:02.915Z

- Ticker: CLRB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001279704
- Website: cellectar.com

## About

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

## Latest CLRB news and filings

- 2026-11-04 14:00 UTC [Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition](https://www.quantisnow.com/insight/cellectar-biosciences-to-present-three-posters-highlighting-durable-clinical-activity-6771637)
- 2026-11-02 13:00 UTC [Earnings Date] [Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026](https://www.quantisnow.com/insight/cellectar-biosciences-to-report-third-quarter-financial-results-and-host-6766173)
- 2026-10-27 11:15 UTC [Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131](https://www.quantisnow.com/insight/cellectar-biosciences-reports-case-study-highlighting-complete-response-lasting-more-6758465)
- 2026-10-15 11:00 UTC [Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia](https://www.quantisnow.com/insight/cellectar-biosciences-presents-compelling-efficacy-data-from-phase-2b-clover-6747166)
- 2026-09-29 11:30 UTC [Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia](https://www.quantisnow.com/insight/cellectar-biosciences-to-present-compelling-efficacy-data-from-phase-2-6728373)
- 2026-08-14 10:02 UTC [SEC Form SCHEDULE 13G filed by Cellectar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-cellectar-biosciences-inc-6681665)
- 2026-08-13 11:25 UTC [SEC Form 8-K] [Cellectar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cellectar-biosciences-inc-filed-sec-form-8-k-results-of-operations-6679263)
- 2026-08-13 11:15 UTC [Public Offering] [Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates](https://www.quantisnow.com/insight/cellectar-biosciences-reports-second-quarter-2026-financial-results-and-provides-6679238)
- 2026-08-13 11:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Cellectar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-cellectar-biosciences-inc-6679202)
- 2026-07-30 12:05 UTC [Earnings Date] [Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026](https://www.quantisnow.com/insight/cellectar-biosciences-to-report-second-quarter-financial-results-and-host-6655172)
- 2026-07-15 11:30 UTC [Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers](https://www.quantisnow.com/insight/cellectar-biosciences-announces-publication-of-phase-1-study-of-iopofosine-6637560)
- 2026-07-11 01:00 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Consultant Loren Stefan](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-consultant-loren-stefan-6634584)
- 2026-07-10 21:13 UTC [SEC Form 8-K] [Cellectar Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cellectar-biosciences-inc-filed-sec-form-8-k-leadership-update-submission-6634420)
- 2026-07-09 01:13 UTC [SEC Form 4] [SEC Form 4 filed by CFO Kolean Chad J](https://www.quantisnow.com/insight/sec-form-4-filed-by-cfo-kolean-chad-j-6632155)
- 2026-07-09 01:10 UTC [SEC Form 4] [SEC Form 4 filed by Director Driscoll Frederick W](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-driscoll-frederick-w-6632153)
- 2026-07-09 01:09 UTC [SEC Form 4] [SEC Form 4 filed by Director Chanan-Khan Asher](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-chanan-khan-asher-6632151)
- 2026-07-09 01:07 UTC [SEC Form 4] [SEC Form 4 filed by President & CEO Caruso James V](https://www.quantisnow.com/insight/sec-form-4-filed-by-president-ceo-caruso-james-v-6632150)
- 2026-07-09 01:06 UTC [SEC Form 4] [SEC Form 4 filed by Director Gu Andrew](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-gu-andrew-6632149)
- 2026-07-09 01:05 UTC [SEC Form 4] [SEC Form 4 filed by Chief Operating Officer Longcor Jarrod](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-operating-officer-longcor-jarrod-6632148)
- 2026-07-09 01:04 UTC [SEC Form 4] [SEC Form 4 filed by Director Swirsky Douglas J](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-swirsky-douglas-j-6632146)
- 2026-07-09 01:02 UTC [SEC Form 4] [SEC Form 4 filed by Director Neis John](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-neis-john-6632144)
- 2026-07-09 01:00 UTC [SEC Form 4] [SEC Form 4 filed by Consultant Loren Stefan](https://www.quantisnow.com/insight/sec-form-4-filed-by-consultant-loren-stefan-6632143)
- 2026-06-09 21:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Gu Andrew](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-gu-andrew-6595735)
- 2026-06-05 16:56 UTC [SEC Form SCHEDULE 13G filed by Cellectar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-cellectar-biosciences-inc-6590897)
- 2026-06-02 10:01 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Cellectar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-cellectar-biosciences-inc-6582981)
- 2026-06-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Cellectar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-cellectar-biosciences-inc-6582971)
- 2026-06-01 12:05 UTC [Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting](https://www.quantisnow.com/insight/cellectar-biosciences-to-highlight-compelling-new-efficacy-data-from-phase-6580750)
- 2026-05-29 12:50 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Cellectar Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-cellectar-biosciences-inc-6578513)
- 2026-05-28 21:14 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Cellectar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-cellectar-biosciences-inc-6577726)
- 2026-05-28 21:13 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Cellectar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-cellectar-biosciences-inc-6577724)
- 2026-05-19 21:05 UTC [SEC Form S-1] [SEC Form S-1 filed by Cellectar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-cellectar-biosciences-inc-6563345)
- 2026-05-18 21:00 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Cellectar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-cellectar-biosciences-inc-6560811)
- 2026-05-18 20:15 UTC [SEC Form 8-K] [Cellectar Biosciences Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/cellectar-biosciences-inc-filed-sec-form-8-k-leadership-update-6560282)
- 2026-05-15 12:17 UTC [Analyst Coverage Initiated] [Ladenburg Thalmann initiated coverage on Cellectar Biosciences with a new price target](https://www.quantisnow.com/insight/ladenburg-thalmann-initiated-coverage-on-cellectar-biosciences-with-a-new-6555861)
- 2026-05-14 11:20 UTC [SEC Form 8-K] [Cellectar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cellectar-biosciences-inc-filed-sec-form-8-k-results-of-operations-6552340)
- 2026-05-14 11:15 UTC [Public Offering] [Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates](https://www.quantisnow.com/insight/cellectar-biosciences-reports-first-quarter-2026-financial-results-and-provides-6552333)
- 2026-05-14 11:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Cellectar Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-cellectar-biosciences-inc-6552296)
- 2026-05-12 00:07 UTC [Insider Buy] [Chief Operating Officer Longcor Jarrod bought $24,998 worth of shares (8,680 units at $2.88), increasing direct ownership by 74% to 20,451 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-longcor-jarrod-bought-24998-worth-of-shares-6546205)
- 2026-05-12 00:05 UTC [Insider Buy] [Chief Executive Officer Caruso James V bought $24,998 worth of shares (8,680 units at $2.88), increasing direct ownership by 75% to 20,318 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-caruso-james-v-bought-24998-worth-of-6546203)
- 2026-05-11 12:05 UTC [Earnings Date] [Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026](https://www.quantisnow.com/insight/cellectar-biosciences-to-report-first-quarter-financial-results-and-host-6543844)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CLRB
- Earnings history: https://www.quantisnow.com/earnings/CLRB
- Dividend history: https://www.quantisnow.com/dividends/CLRB
- Insider transactions: https://www.quantisnow.com/insiders/CLRB
- Options chain: https://www.quantisnow.com/options/CLRB
- SEC 8-K filings only: https://www.quantisnow.com/company/CLRB/8-k
- RSS and alerts for CLRB: https://www.quantisnow.com/docs/rss-feeds.md